Nasdaq:US$13.41 (-0.23) | HKEX:HK$21.15 (+0.00) | AIM:£2.22 (+0.02)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases | 29 Oct 2022

NANETS 2022:An open-label, Phase 1b/2 study of surufatinib in combination with tislelizumab in patients with advanced neuroendocrine tumors